0QNV Stock Overview Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Addex Therapeutics Ltd Competitors Price History & Performance
Summary of share price highs, lows and changes for Addex Therapeutics Historical stock prices Current Share Price CHF 0.062 52 Week High CHF 0.19 52 Week Low CHF 0.055 Beta 1.89 1 Month Change n/a 3 Month Change n/a 1 Year Change n/a 3 Year Change -94.27% 5 Year Change -96.23% Change since IPO -96.92%
Recent News & Updates Addex Therapeutics Ltd to Report Fiscal Year 2024 Results on Mar 24, 2025
Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024 Sep 10
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration Aug 27
Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium Jul 15
Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024 Jun 08
Full year 2023 earnings released: CHF0.14 loss per share (vs CHF0.46 loss in FY 2022) Apr 20 See more updates Addex Therapeutics Ltd to Report Fiscal Year 2024 Results on Mar 24, 2025
Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024 Sep 10
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration Aug 27
Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium Jul 15
Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024 Jun 08
Full year 2023 earnings released: CHF0.14 loss per share (vs CHF0.46 loss in FY 2022) Apr 20
Insufficient new directors Apr 18
Addex Therapeutics Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024 Apr 11
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders Apr 05
New major risk - Shareholder dilution Mar 30
Insufficient new directors Mar 12 Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million. Jan 31
Insufficient new directors Jan 24 Addex Therapeutics Ltd to Report First Half, 2024 Results on Aug 12, 2024
Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients Nov 15
Addex Regains Nasdaq Listing Compliance Nov 08
Addex Therapeutics Announces Data Published in Brain Sep 05 Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC Aug 04
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder Jul 25
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency May 19
Addex Therapeutics Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study May 11
No longer forecast to breakeven Mar 02
Addex Regains Nasdaq Listing Compliance Feb 10
No longer forecast to breakeven Feb 04
No longer forecast to breakeven Jan 21 Addex Therapeutics Ltd to Report Fiscal Year 2022 Results on Mar 13, 2023
No longer forecast to breakeven Dec 29
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Nov 03
No longer forecast to breakeven Oct 28
No longer forecast to breakeven Sep 13
No longer forecast to breakeven Aug 04 Addex Therapeutics Ltd announced that it has received funding from Armistice Capital LLC Jul 28
Addex Therapeutics Ltd announced that it expects to receive funding from Armistice Capital LLC Jul 23
No longer forecast to breakeven Jun 30
Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate Jun 17
Addex Therapeutics Ltd Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study May 27
First quarter 2022 earnings released: CHF0.15 loss per share (vs CHF0.079 loss in 1Q 2021) May 06
Forecast to breakeven in 2024 Apr 27
Addex Therapeutics Ltd Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study Apr 13
Addex Therapeutics Ltd Expands Pipeline with Selective M4 Positive Allosteric Modulator Program Apr 06
Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022 Mar 31
Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022 Mar 29
Forecast to breakeven in 2023 Feb 24
Forecast to breakeven in 2023 Jan 11
Addex Therapeutics Ltd announced that it has received CHF 5.427937 million in funding from Armistice Capital LLC Dec 22
Addex Therapeutics Ltd announced that it expects to receive CHF 5.427937 million in funding from Armistice Capital LLC Dec 19
Addex Therapeutics Ltd Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm Oct 01
Addex Therapeutics Starts Phase 2 Clinical Study of ADX71149 for Epilepsy Jun 08
Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia May 19
First quarter 2021 earnings released: CHF0.08 loss per share (vs CHF0.16 loss in 1Q 2020) May 06
Revenue beats expectations Mar 12
Full year 2020 earnings released: CHF0.48 loss per share (vs CHF0.56 loss in FY 2019) Mar 12 Addex Therapeutics Ltd to Report Q1, 2021 Results on May 03, 2021
Enamine Ltd. Extends Collaboration with Addex Therapeutics Ltd Feb 25
Addex Therapeutics Announces New Treatment Option for Severe Alcohol Use Disorder Feb 18
Addex Therapeutics Ltd to Report Fiscal Year 2020 Results on Mar 08, 2021 Feb 17
Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy Jan 22
Addex Therapeutics Ltd to Report Q3, 2020 Results on Nov 03, 2020 Nov 03
First half earnings released Aug 13
Addex Therapeutics Ltd to Report First Half, 2020 Results on Aug 12, 2020 Aug 10 Shareholder Returns 0QNV GB Biotechs GB Market 7D n/a -4.2% -2.6% 1Y n/a -24.5% 2.4%
See full shareholder returns
Return vs Industry: Insufficient data to determine how 0QNV performed against the UK Biotechs industry .
Return vs Market: Insufficient data to determine how 0QNV performed against the UK Market .
Price Volatility Is 0QNV's price volatile compared to industry and market? 0QNV volatility 0QNV Average Weekly Movement n/a Biotechs Industry Average Movement 6.9% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0QNV's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0QNV's volatility change over the past year.
About the Company Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Show more Addex Therapeutics Ltd Fundamentals Summary How do Addex Therapeutics's earnings and revenue compare to its market cap? 0QNV fundamental statistics Market cap CHF 5.21m Earnings (TTM ) -CHF 12.67m Revenue (TTM ) CHF 592.36k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0QNV income statement (TTM ) Revenue CHF 592.36k Cost of Revenue CHF 6.69m Gross Profit -CHF 6.09m Other Expenses CHF 6.58m Earnings -CHF 12.67m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 24, 2025
Earnings per share (EPS) -0.13 Gross Margin -1,028.84% Net Profit Margin -2,139.51% Debt/Equity Ratio 0%
How did 0QNV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 20:54 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Addex Therapeutics Ltd is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Leonildo Delgado Baader Helvea Equity Research Bob Pooler Bank am Bellevue Silvia Schanz Bank Vontobel AG
Show 8 more analysts 
